Amirah AzzeriMohd Noor Afiq RamleeMohd Iqbal Mohd NoorMohd Hafiz JaafarThinni Nurul RochmahMaznah Dahlui2024-05-292024-05-2920222023-1-26Azzeri, A.; Ramlee, M.N.A.; Noor, M.I.M.; Jaafar, M.H.; Rocmah, T.N.; Dahlui, M. Economic Burden of SARS-CoV-2 Patients with Multi-Morbidity: A Systematic Review Protocol. Int. J. Environ. Res. Public Health 2022, 19, 13157. https:// doi.org/10.3390/ijerph1920131571660-460110.3390/ijerph192013157https://www.mdpi.com/1660-4601/19/20/13157https://www.scopus.com/record/display.uri?eid=2-s2.0-85140914884&origin=resultslist&sort=plf-f&src=s&sid=ff7b2cafb526bfeca0fe6ae95dfa2def&sot=b&sdt=b&s=TITLE-ABS-KEY%28%22%09Economic+Burden+Of+Sars-cov-2+Patients+With+Multi-morbidity%3A+A+Systematic+Review+Protocol%22%29&sl=113&sessionSearchId=ff7b2cafb526bfeca0fe6ae95dfa2defhttps://oarep.usim.edu.my/handle/123456789/10516Volume 19 Issue 20Economic burden issues in SARS-CoV-2 patients with underlying co-morbidities are enormous resources for patient treatment and management. The uncertainty costs for clinical management render the healthcare system catatonic and incurs deficits in national annual budgets. This article focuses on systematic steps towards selecting and evaluating literature to uncover gaps and ways to help healthcare stakeholders optimize resources in treating and managing COVID-19 patients with multi-morbidity. A systematic review of all COVID-19 treatment procedures with co-morbidities or multi-morbidity for the period from 2019 to 2022 was conducted. The search includes studies describing treatment costs associated with multi- or co-morbidity cases for infected patients and, if concurrently reported, determining recurring expenses. Study selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Galbraith plots and I2 statistics will be deployed to assess heterogeneity and to identify potential sources. A backward elimination process will be applied in the regression modelling procedure. Based on the number of studies retrieved and their sample size, the subgroup analysis will be stratified on participant disease category, associated total costs, and degree of freedom in cost estimation. These studies were registered in the PROSPERO registry (ID: CRD42022323071).en-USCOVID-19; economic burden; comorbidity; cardio/cerebrovascular; diabetes; hypertension; respiratory diseasesArticle1111920